HT
PTGX icon

Headlands Technologies’s Protagonist Therapeutics PTGX Stock Holding History

Headlands Technologies’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,957
Closed -$312K – 938
2026
Q1 		$312K Sell
2,957
-14,122
-83% -$1.25M 0.04% 488
2025
Q4 		$1.49M Buy
+17,079
New +$1.4M 0.12% 193

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Headlands Technologies's PTGX Position: Q2 2026 in Review

Headlands Technologies sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 2,957 shares — an estimated $312K sold.

Headlands Technologies first reported a position in PTGX in Q4 2025 and held it in 2 quarters. The position peaked at $1.49M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Headlands Technologies reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 2,957 Protagonist Therapeutics shares in Q2 2026, an estimated $312K.
  • Headlands Technologies first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 2 quarters.
  • Headlands Technologies's Protagonist Therapeutics position peaked at $1.49M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.